Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1
Most Cited Paper
in Growth Hormone and Insulin-like Growth Factors
18 Months Post-Publication
Class of 2026
“Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
acromegaly · Octreotide · CAM2029 · subcutaneous depot · FluidCrystal technology · Insulin-like growth factor 1 · growth hormone · biochemical control · Octreotide · Lanreotide · self-administration · quality of life · treatment satisfaction · Randomized double-blind placebo-controlled trial · dose reduction
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Growth Hormone and Insulin-like Growth Factors Papers, Class of 2026. https://pri.pepkio.com/top-papers/growth-hormone-and-insulin-like-growth-factors/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459